In the open-label extension phase of their study, 3 brain hemorrhage-related deaths were attributed to lecanameb (combined with anticoagulants in 2 patients and combined with IV tissue plasminogen activator for an acute cerebrovascular accident (CVA) in 1 patient) (7, 8, 21). This evidence concerns the gene PLAT and intracranial hemorrhage.